Abstract

Abstract Objectives To evaluate effectiveness of prophylactic drugs in treatment of VM patients. Second to compare between each drug for its efficacy for treatment of VM patients Subjects and Methods Forty-five subjects divided into 3 groups were included in the present study. Group A, 15 subjects received Cinnarzine with mean age of 37.7 years. Group B, 15 subjects received Inderal with mean age of 38.3 years. Group C, 15 subjects received Topamax with mean age of 39 years diagnosed with vestibular migraine. They were subjected to a Dizziness Handicap Inventory questionnaire (DHI), visual analogue scale (VAS), neurological examination, vestibular office tests, videonystagmography (VNG) and sensory organization test (SOT) of computerized dynamic posturography (CDP) before and after receiving treatment according to grouping. Results 3 months after treatment, the mean number of total vertiginous attacks decreased from (14.5 ±9.2) to (7.3 ± 7.8), from (11.5 ±6.6) to (5.2 ± 4.1) and (13.1 ±8.6) to (4.1 ± 3) in Cinnarzine, Propranolol (Inderal) and topiramate (Topamax) groups respectively. DHI scores decreased from (50 ± 12.7) to (34.7± 12.5), (49.7 ± 11.2) to (32.4± 15.6) and (52.7 ±11.2) to (28.3 ± 9.2) in Propranolol (Inderal) and topiramate (Topamax) groups respectively. Conclusions This study provided that all three drugs are effective for ameliorating vertiginous attacks in VM patients; also, the treatment effects were similar in three groups with no significant difference.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.